Hospital Universitario Severo Ochoa

Running trials

• Not yet recruiting

  Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma

  NCT07858123· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  Heart Failure in Women: Epidemiological and Prognostic Insights

  NCT07847983· Carolina Ortiz Cortes· Source

• Not yet recruiting

  Optimizing the Use of Aspirin for the Prevention of Preeclampsia

  NCT07665853· Phase 3· Hospital Universitari Vall d'Hebron Research Institute· Source

• Recruiting

  A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1)

  2025-524040-35-00· Phase 3· Generate Biomedicines Inc.· Source

• Recruiting

  Grass Immunotherapy for Rhinitis and Asthma (GIRA)

  2025-521736-10-00· Phase 3· LETI Pharma S.L.U.· Source

• Recruiting

  Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES)

  2025-521709-42-00· Phase 3· LETI Pharma S.L.U.· Source

• Not yet recruiting

  Treatment for Ph-negative ALL for Adults up to 65 Years

  NCT07443592· PETHEMA Foundation· Source

• Not yet recruiting

  Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

  2025-521989-95-00· Phase 1/2· Oncomatryx Biopharma S.L.· Source

• Recruiting

  PALACE: Cemiplimab Trial According to ctDNA Levels

  NCT06917573· Phase 2· Fundación GECP· Source

• Recruiting

  Non-Steroidal Anti-Inflammatory Drugs in Acute Myocarditis

  NCT06686862· Phase 3· Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III· Source

• Recruiting

  Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

  NCT06943469· Société des Produits Nestlé (SPN)· Source

• Recruiting

  Advanced Invasive Diagnosis Strategy for Post-PCI Patients With Stable Coronary Syndromes Undergoing Coronary Angiography

  NCT07638137· Fundacion Investigacion Interhospitalaria Cardiovascular· Source

• Recruiting

  Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

  NCT06724159· Spanish Oncology Genito-Urinary Group· Source

• Active, not recruiting

  Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

  NCT06543914· AbbVie· Source

• Recruiting

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

  NCT05930275· AbbVie· Source

• Active, not recruiting

  Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squamous non-small cell lung cancer patients

  2023-507448-36-00· Phase 3· Samsung Bioepis Co. Ltd.· Source

• Recruiting

  Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

  NCT05398094· Phase 2· Fundación GECP· Source

• Active, not recruiting

  Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy: (REMOVE)

  2023-504946-70-00· Phase 4· Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia· Source

• Active, not recruiting

  Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

  NCT04675333· Phase 2· ALX Oncology Inc.· Source

• Active, not recruiting

  Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

  NCT04675294· Phase 2· ALX Oncology Inc.· Source

• Active, not recruiting

  Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

  NCT04595565· Phase 3· GBG Forschungs GmbH· Source

• Recruiting

  A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)

  NCT02819882· Spanish Breast Cancer Research Group· Source

• Active, not recruiting

  A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

  NCT02130362· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma4 recruiting
• Lung cancer3 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Bladder cancer1 recruiting
• Coronary artery disease1 recruiting
• Heart failure1 recruiting
• Kidney cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Myocarditis1 recruiting
• Prostate cancer1 recruiting
• Sarcoma1 recruiting

Closed trials

• Completed

  Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma

  NCT07354282· Spanish Oncology Genito-Urinary Group· Source

• Recruiting

  A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients

  NCT06578078· Phase 3· Fundación para la Investigación del Hospital Clínico de Valencia· Source

• Completed

  Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy

  2023-507438-25-00· Phase 1· Samsung Bioepis Co. Ltd.· Source

• Completed

  Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

  NCT04776447· Phase 2· Fundación GECP· Source

• Completed

  Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

  NCT04864795· Vifor (International) Inc.· Source

• Completed

  Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

  NCT03982394· AbbVie· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Immune thrombocytopenia (ITP)4 works · 0 trials